Lung cancer screening: 360 degree review by Herold, Christian J & McLoud, Theresa C
Lung cancer screening: 360 degree review
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Herold, Christian J., and Theresa C McLoud. 2015. “Lung
cancer screening: 360 degree review.” Cancer Imaging 15
(Suppl 1): O13. doi:10.1186/1470-7330-15-S1-O13. http://
dx.doi.org/10.1186/1470-7330-15-S1-O13.
Published Version doi:10.1186/1470-7330-15-S1-O13
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:23474036
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
ORAL PRESENTATION Open Access
Lung cancer screening: 360 degree review
Christian J Herold1*, Theresa C McLoud2
From International Cancer Imaging Society Meeting and 15th Annual Teaching Course (ICIS 2015)
London, UK. 5-7 October 2015
The most compelling evidence supporting the use of low
dose computed tomography in the screening of high risk
populations for lung cancer was generated by the National
Lung Cancer Screening Trial carried out in the United
States by the National Cancer Institute and the American
College of Radiology Imaging Network.[1] This trial was a
randomized prospective study which included over 53,000
participants. The two arms consisted of patients who were
randomized to low dose CT and those who received stan-
dard radiography. Data from the NLST demonstrated that
screening reduced mortality by 20% in the CT arm. Other
smaller studies carried out in Europe have reported no
mortality benefit. However, these studies included a
younger screening population and had a smaller number
of participants and probably did not have the power to
show a mortality benefit.[2] Major medical societies and
US government agencies such as US Preventative Services
Task Force and now the Center for Medicare Services
have now recommended LDCT. These decisions not only
recommend screening but require US insurance compa-
nies and Medicare in the US to provide reimbursement.[3]
Some of the caveats of screening result from the limits
of generalization of the NLST results based on risk
groups and demographics. There are also potential
harms and complications from the LDCT screening
which include radiation exposure, over diagnosis, the
use of invasive procedures for diagnosis and the high
false positive rate. [1,4]
Lung cancer screening could have a strong impact on
health care in Europe where there are over 268,000 lung
cancer deaths per annum. Screening could save thou-
sands of lives. However, lung cancer screening is cur-
rently not reimbursed and there are no screening
programs accessible through health care systems or
health plans. Important factors for lung cancer screening
in Europe include refinement of inclusion criteria and
stratification of risks, modeling of cost effectiveness
data, and inclusion of evidence from European trials.
Implementation of screening programs in Europe will
require a collaborative effort among professional special-
ties, societies, organizations, and additional trial data.
The American College of Radiology has developed a
reporting system for lung cancer screening designated
“Lung Rads.” [5] It is a reporting system which is very
similar to Bi-Rads that includes numeric categories. It
associates CT findings with guideline based management
decisions. LDCT findings are categorized from 1-4
according to the likelihood of malignancy. 1 and 2 are
considered benign findings and 3 and 4 have a higher
probability of malignancy. There are descriptions for
each of the 4 categories plus an enumeration of findings.
The categories include characterization of nodules
including size and density (solid, part-solid, or non-
solid ground glass). In addition to the categories and
findings there are guidelines for management in each
category with estimates of the probability of malignancy
and the estimated population prevalence.
Constructing a lung cancer screening program in your
institution presents many challenges. (6) Stake holders
include the hospital leadership, referral providers, a multi-
disciplinary team, and support staff. Patient and physician
outreach and education are essential. Standard protocols
should be developed for image acquisition. Ideally image
review should be performed by radiologists experienced in
chest CT and nodule detection. Imaging software that
combines CAD and volumetric measurements is desirable.
Findings should be recorded according to the lung ima-
ging reporting and data system such as Lung Rads. Com-
munication of results to both the patient and physician is
important and such communication should be stratified
according to urgency.
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